Blockade of the renin‐angiotensin‐aldosterone system in patients with arrhythmogenic right ventricular dysplasia: A double‐blind, multicenter, prospective, randomized, genotype‐driven study (BRAVE study)
- 25 March 2018
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 41 (3) , 300-306
Abstract
Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy characterized by the progressive replacement of cardiomyocytes by fatty and fibrous tissue in the right ventricle (RV). These infiltrations lead to cardiac electrical instability and ventricular arrhythmia. Current treatment for ARVD is empirical and essentially based on treatment of arrhythmia. Thus, there is no validated treatment that will prevent the deterioration of RV function in patients with ARVD. The aim of the BRAVE study is to evaluate the effect of ramipril, an angiotensin‐converting enzyme inhibitor, on ventricular myocardial remodeling and arrhythmia burden in patients with ARVD. Despite the fact that myocardial fibrosis is one of the structural hallmarks of ARVD, no study has tested an antifibrotic drug in ARVD patients. The trial is a double‐blind, parallel, multicenter, prospective, randomized, phase 4 drug study. Patients will be randomized into 2 groups, ramipril or placebo. The 120 patients (60 per group) will be enrolled by 26 centers in France. Patients will be followed up every 6 months for 3 years. The 2 co–primary endpoints are defined as the difference of telediastolic RV volume measured by magnetic resonance imaging between baseline and 3 years of follow‐up, and the change in arrhythmia burden during the 3 years of follow‐up. A decrease in RV and/or left ventricular deterioration and in arrhythmia burden are expected in ARVD patients treated with ramipril. This reduction will improve quality of life of patients and will reduce the number of hospitalizations and the risk of terminal heart failure.Keywords
This publication has 21 references indexed in Scilit:
- Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritisArthritis Research & Therapy, 2012
- Disproportionate Exercise Load and Remodeling of the Athlete's Right VentricleMedicine & Science in Sports & Exercise, 2011
- Load-Reducing Therapy Prevents Development of Arrhythmogenic Right Ventricular Cardiomyopathy in Plakoglobin-Deficient MiceJACC, 2011
- Lack of Uniform Progression of Endocardial Scar in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy and Ventricular TachycardiaCirculation: Arrhythmia and Electrophysiology, 2010
- Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/DysplasiaCirculation, 2010
- A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathyCardiovascular Research, 2009
- Arrhythmogenic right ventricular cardiomyopathy: Clinicopathologic correlation based on a revised definition of pathologic patternsHuman Pathology, 2001
- Arrhythmogenic right ventricular cardiomyopathy: An updateCardiovascular Pathology, 2001
- Arrhythmogenic Right Ventricular DysplasiaAnnual Review of Medicine, 1999
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991